Lv52
1540 积分 2022-08-08 加入
Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma
12天前
已完结
Ulcerative Colitis in Adults
24天前
已完结
Risankizumab for Ulcerative Colitis
24天前
已关闭
Risankizumab for Ulcerative Colitis
24天前
已完结
Serum contents of IL-23 and IL-17 in the patients with ulcerative colitis and the clinical significance
28天前
已关闭
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
1个月前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
1个月前
已完结
Risankizumab for Ulcerative Colitis
1个月前
已关闭
Risankizumab for Ulcerative Colitis
1个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
